BioCentury | Jan 15, 2021
Politics, Policy & Law

New relevance, old guard: Biden throws weight behind science, puts Lander in Cabinet, keeps Collins at NIH

President-elect Joe Biden is raising the profile of science in his administration by elevating the role of presidential science advisor to a Cabinet position, naming the Broad Institute’s Eric Lander to the post, and nominating...
BioCentury | Oct 17, 2020
Politics, Policy & Law

Getting FDA back on track

Regardless of the outcome of the elections, FDA is likely to have a new commissioner next year, one who will step into a leadership vacuum that is exhausting the agency’s supply of credibility and...
BioCentury | Aug 1, 2020
Product Development

Will Biocon’s COVID-19 anti-inflammatory succeed where IL-6 blockers have failed?

This article has been updated to reflect that the Indian health ministry did not include Alzumab itolizumab among the drugs on its COVID-19 treatment protocol. With an Indian EUA for Alzumab, Biocon is now planning...
BioCentury | Jun 30, 2020
Product Development

CanSino vaccine first to gain approval as Gilead reveals remdesivir price

CanSino received “military specially-needed drug approval” in China for its vaccine, making it the first vaccine to be authorized for use albeit in a limited population. The announcement came as Gilead Sciences Inc. (NASDAQ:GILD) announced...
BioCentury | Jun 23, 2020
Tools & Techniques

AI tools against COVID-19: a view from where the rubber hits the road

Making machine learning an effective tool in the fight against COVID-19 requires broad access to data, scrupulous checks for bias, and strategies to balance speed and accuracy, according to researchers with AI-based diagnostics and literature-mining...
BioCentury | May 30, 2020
Product Development

The critical path to COVID-19 therapies

The path to safe, effective COVID-19 therapies is crowded and poorly marked. There is an urgent need to fast-track a manageable number of therapies, illuminate every step along the route, and create signposts for research,...
BioCentury | Jan 16, 2020
Politics, Policy & Law

Francis Collins’ 2020 vision for NIH

In his tenth year as NIH Director, Francis Collins is expanding the reach of marquee programs launched under his tenure, and growing the institutes’ footprint in artificial intelligence. In a conversation with BioCentury, Collins identified...
BioCentury | Sep 14, 2019

Mark Schoenebaum: Setting the gold standard

In a business dominated by numbers, calculations, dollars and cents, Mark Schoenebaum understood that humanity, kindness and humility are paramount. This understanding gave him a boost that allowed him to reinvent what it means to...
BioCentury | Sep 13, 2019
Tools & Techniques

Enzymes aim to beat chemistry by creating longer, speedier, cleaner DNA strands

The first new chemistry for DNA writing in 30 years is gathering steam, with enzymatic synthesis startups developing platforms to generate longer, purer DNA strands in record time. While the new players aim to outperform...
BioCentury | Aug 22, 2019
Politics & Policy

Changing of the guard at NICE

When Andrew Dillon steps down as NICE's chief executive in March 2020, his successor will be tasked with leading an agency that faces an increasingly complex and fast-moving medicines landscape. The U.K. agency is already...
Items per page:
1 - 10 of 118